Get started
Author

Kseniia Uzhegova

Observed name: K. Uzhegova
ORCID: 0009-0007-8341-8558
Observed ORCID: 0009-0007-8341-8558
OpenAlex ID: A5116307282
Patient-Reported Financial Toxicity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
2026 · Vladislav Kovalik, Armando Sardi, et al. · Annals of Surgical Oncology · 2
Controlling perfusion temperature relates to better outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
2025 · Felipe Lopez-Ramirez, Kseniia Uzhegova, et al. · European Journal of Surgical Oncology · 1
Recurrence Incidence and Optimal Surveillance After Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Mucinous Appendix Cancer
2025 · V. Kovalik, A. Sardi, et al. · Annals of Surgical Oncology · 1
Prognostic significance of signet ring cell predominance in peritoneal metastases from appendix cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
2026 · Kseniia Uzhegova, Vadim Gushchin, et al. · European Journal of Surgical Oncology
ASO Visual Abstract: Patient-Reported Financial Toxicity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
2026 · Vladislav Kovalik, Armando Sardi, et al. · Annals of Surgical Oncology
PDF
Clinical characteristics and outcomes of patients with goblet cell adenocarcinoma of the appendix treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC): A multicenter cohort study
2026 · Sergei Iugai, Vadim Gushchin, et al. · European Journal of Surgical Oncology
Beyond surgical complexity: Impact of perioperative risk on survival after extensive cytoreduction and hyperthermic intraperitoneal chemotherapy for ovarian cancer
2026 · Luis Felipe Falla Zuniga, Teresa Diaz-Montes, et al. · Gynecologic Oncology
The role of platinum-free interval in recurrent ovarian cancer patients undergoing secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
2025 · Sergei Iugai, Teresa Diaz-Montes, et al. · Gynecologic Oncology
Geographic and socioeconomic factors associated with hyperthermic intraperitoneal chemotherapy use in advanced ovarian cancer: A National Cancer Database study
2025 · Vladislav Kovalik, Armando Sardi, et al. · Gynecologic Oncology
Braving the heat: Hyperthermic intraperitoneal chemotherapy outcomes in primary and interval debulking surgery for FIGO stage IV ovarian cancer
2025 · Luis Felipe Falla-Zuniga, Armando Sardi, et al. · Gynecologic Oncology
The Effect of Prior Nondefinitive Surgery on Perioperative Outcomes and Survival in Mucinous Appendix Cancer Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
2025 · Sergei Iugai, Vadim Gushchin, et al. · The American Surgeon
Extended neoadjuvant chemotherapy in advanced ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: decision drivers and surgical outcomes
2025 · Kseniia Uzhegova, Armando Sardi, et al. · Gynecologic Oncology Reports
Association between time to adjuvant chemotherapy and survival in ovarian cancer patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
2025 · Sergei Iugai, Armando Sardi, et al. · Gynecologic Oncology Reports
Works count: 13
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type